- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost-Effective Medication Access in Demodex Blepharitis Treatment
An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.
Demodex blepharitis is the leading reason that patients visit eye physicians, making up 40% to 50% of eye care professional appointments. Many patients are misdiagnosed and mistreated for aqueous-deficient dry eye with expensive immunomodulators instead of given the correct Demodex blepharitis diagnosis. Correct diagnosis and treatment with Xdemvy(lotilaner ophthalmic solution) significantly cuts costs.
Once diagnosed, Demodex blepharitis responds well to treatment. Lotilaner is a safe and effective 6-week, twice-daily course that improves ocular surface disease for at least 1 year, showing long-term stability for this previously unmanaged chronic condition.
It is important that patients understand Demodex pathogenesis because an eyelash mite infestation, in addition to clinical outcomes, usually motivates treatment adherence.
Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
